Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Ultragenyx (RARE). Shares have added about 9.6% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Ultragenyx due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

How Have Estimates Been Moving Since Then?

It turns out, fresh estimates have trended upward during the past month.

VGM Scores

Currently, Ultragenyx has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Ultragenyx has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Ultragenyx belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Agios Pharmaceuticals (AGIO), has gained 20.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.

Agios Pharmaceuticals reported revenues of $8.73 million in the last reported quarter, representing a year-over-year change of +6.6%. EPS of -$1.55 for the same period compares with -$1.45 a year ago.

Agios Pharmaceuticals is expected to post a loss of $1.74 per share for the current quarter, representing a year-over-year change of -3%. Over the last 30 days, the Zacks Consensus Estimate has changed +4.6%.

Agios Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research